Pharmacological Inhibition Of IRAP As A Novel Antifibrotic Strategy
Funder
National Health and Medical Research Council
Funding Amount
$1,036,370.00
Summary
There are very few treatments that can reduce heart stiffening, called fibrosis, which is seen in patients with high blood pressure or in patients who have had a heart attack. This project will test new drugs that we have developed that act by a unique mechanism to reverse or prevent cardiovascular disease in patients with poorly-functioning hearts and blood vessels.
Is Overactive Bladder A 'Bladder Itch'? Identification Of Itch Specific Pathways Within The Bladder
Funder
National Health and Medical Research Council
Funding Amount
$720,585.00
Summary
Overactive bladder is a leading cause of nocturia, urgency and incontinence. These symptoms arise from sensory nerve fibres in the bladder. We have identified key irritant mechanisms, including the bile acid receptor TGR5 and Mrgpr family, thought to only exist in the skin, also innervate the bladder. We hypothesis that the clinical entity overactive bladder, is triggered by pathological activation of bladder afferents by such irritants and that overactive bladder is essentially a bladder itch.
Research Fellowship: Protection Of Myocardial Function In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Heart failure (HF) is a major cause of death in Australia. A/Prof Rebecca Ritchie heads Heart Failure Pharmacology at Baker IDI. Her research focuses on new drug strategies to maintain heart function in response to diabetes & heart attack, common precursors of HF. Many of the treatments discovered from this work are naturally-occurring antioxidants; enhancing their activity will ultimately reduce progression to HF & death in the >3 million Australians affected by these disorders.
Investigating A Novel Agent To Limit Brain Injury And Post-stroke Complications
Funder
National Health and Medical Research Council
Funding Amount
$412,429.00
Summary
Stroke is a leading cause of morbidity and mortality worldwide, but treatment options remain limited. The goal of this research project will be to examine the potential of new agent to protect the brain against stroke and to also treat complications that typically occur after stroke including infection and weight loss. It is anticipated that this project will ultimately lead to the development of an effective stroke therapy.
Molecular Characterisation Of The Glucagon-like Peptide 1 Receptor
Funder
National Health and Medical Research Council
Funding Amount
$681,953.00
Summary
The glucagon-like peptide 1 receptor is a major target for treatment of Type 2 diabetes and obesity. However, the development of drugs for this receptor is challenging due to limited understanding of potential sites of drug interaction and how individual drugs may differentially change signalling from the receptor. This project will address these critical knowledge gaps, which may allow for improved therapeutic outcomes.
Understanding The Major Class Of Cell Surface Drug Targets
Funder
National Health and Medical Research Council
Funding Amount
$7,595,840.00
Summary
G Protein-Coupled Receptors (GPCRs) form the largest family of receptors and drug targets in living organisms. Currently, the major reason that new drugs fail to reach the clinic is lack of appropriate drug effect (approx. 30%). Thus, we need a better understanding of how GPCRs work and how this relates to disease. Our Program addresses this knowledge gap, using GPCR models that are relevant to treatment of metabolic, inflammatory, cardiovascular and central nervous system disease.
Inhibitors Of Secretory Phospholipases In Diet Induced Obese Rats
Funder
National Health and Medical Research Council
Funding Amount
$581,051.00
Summary
A new drug given to rats fed a high fat-carbohydrate diet shows very promising effects in preventing and treating abdominal obesity, insulin resistance, glucose intolerance, and other risk factors for diabetes and cardiovascular disease. This project will profile biochemical and pharmacological properties of the drug in more detail in order to track down molecular mechanisms of its action and potential therapeutic benefits, guided by studies on rats, biochemical markers, rat and human fat cells.